Simone brings to Inkef 20 years of experience across venture capital and startup creation. Before joining INKEF Simone was CEO of Metabomed, a cancer metabolism company he co-founded while he was Head of the Israel Bioincubator Fund at M Ventures, Simone accumulated his company building experience while at M Ventures, where he established and led several healthcare startups. During that time Simone also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Previously, he was Vice President Business Development at RAD Biomed Accelerator, one of Israel’s leading life science incubators. Simone did his PhD in Structural Biology and Neurobiology at the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology.
I love the sea. I enjoy sailing (working on my skipper license) and I am an avid scuba diver. I also love to hike, especially in the desert. There are plenty of opportunities for all three activities in Israel, where I spend a large part of my time.
Anavo Therapeutics is the first biotech company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. With world-leading scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo is working to unlock the full potential of phosphatase-targeted allosteric modulators for oncology applications.
Cardior Pharmaceuticals is pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Its approach of blocking ClC-1 improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
Scenic Biotech BV is a spinout company of the Netherlands Cancer Institute (NKI) and Oxford University, based in Amsterdam, The Netherlands. It is Scenic Biotech’s mission to harness genetic modifiers to combat disease. The company was founded by Prof Thijn Brummelkamp and Prof Sebastian Nijman.